Kos Azmacort HFA Submission In ’07 Could Lead To Removal Of CFC Version
Executive Summary
Kos plans to submit an NDA for Azmacort HFA in the second half of 2007, which would likely lead to the removal of CFC-containing Azmacort
You may also be interested in...
CFC-Only Asthma Drugs Likely To Lose “Essential Use” Designation
FDA is likely to initiate proceedings to revoke the "essential use" designation for remaining chlorofluorocarbon-propelled asthma drug products following a lack of strong support by FDA's Pulmonary-Allergy Drugs Advisory Committee for continued use of any of the products
CFC-Only Asthma Drugs Likely To Lose “Essential Use” Designation
FDA is likely to initiate proceedings to revoke the "essential use" designation for remaining chlorofluorocarbon-propelled asthma drug products following a lack of strong support by FDA's Pulmonary-Allergy Drugs Advisory Committee for continued use of any of the products
CFC Albuterol To Be Pulled In 2008; FDA Says HFA Makers Need Ramp-Up Time
FDA is basing its Dec. 31, 2008 deadline for the withdrawal of CFC-containing albuterol on the concern that manufacturers will need additional time to ramp-up production of hydrofluoroalkane products